Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2019 Jul 2

PMID 31260538

Citations 13

Authors

Ching-Hua Lin

Feng-Chua Chen

Hung-Yu Chan

Chun-Chi Hsu

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate and compare time to rehospitalization in patients with schizophrenia receiving long-acting injectable antipsychotics (LAIs) after discharge with those receiving oral antipsychotics. Additionally, the trend of LAIs prescription rates was investigated.

Methods: Patients with schizophrenia (n = 13 087), who were discharged from the study hospital from 2006 to 2017, were followed-up under naturalistic conditions in the year after discharge. The primary outcome was time to rehospitalization. Survival analysis was used in the comparisons between LAIs and oral antipsychotics and between FGA-LAIs and SGA-LAIs. Simple linear regression and Cochrane-Armitage trend test were used to test whether a time trend existed for LAIs prescription rates.

Results: In the 1 year following discharge, patients in the LAIs group had a significantly lower rehospitalization rate and a significantly lengthened time to rehospitalization than those in the oral antipsychotics group. Rehospitalization rate and time to rehospitalization were not significantly different in patients receiving FGA-LAIs or SGA-LAIs. A significantly higher percentage of patients treated with FGA-LAIs received anticholinergic agents than those treated with SGA-LAIs. The LAIs prescription rate grew significantly from 2006 to 2017 by an average of 0.5% per year.

Conclusions: LAIs were significantly superior to oral antipsychotics in reducing rehospitalization risk, whereas SGA-LAIs were comparable with FGA-LAIs in reducing rehospitalization risk. However, use of concomitant anticholinergic agents was less frequent in the SGA-LAIs group than in the FGA-LAIs group. Increase in LAIs prescription rate may be due to growing experiences and success among clinicians in treating patients with LAIs.

Citing Articles

Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms.

Reznik A, Karpenko O, Shumakova E, Mudrak A, Sokolov A, Nazimova S Consort Psychiatr. 2025; 5(4):16-38.

PMID: 39980622 PMC: 11839220. DOI: 10.17816/CP15567.

Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: a one-year, real-world, and retrospective mirror image study in China.

Zhou Y, Chen B, Huang Y Front Psychiatry. 2024; 15:1415275.

PMID: 39296858 PMC: 11408208. DOI: 10.3389/fpsyt.2024.1415275.

Predictors of Readmission in Young Adults with First-Episode Psychosis: A Multicentric Retrospective Study with a 12-Month Follow-Up.

Besana F, Civardi S, Mazzoni F, Carnevale Miacca G, Arienti V, Rocchetti M Clin Pract. 2024; 14(4):1234-1244.

PMID: 39051293 PMC: 11270315. DOI: 10.3390/clinpract14040099.

Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006-2021.

Lin T, Lin C Int J Neuropsychopharmacol. 2023; 26(11):808-816.

PMID: 37616565 PMC: 10674076. DOI: 10.1093/ijnp/pyad053.

Factors Influencing Patient and Caregiver Preferences for Antipsychotic Treatment of Schizophrenia in China: A Discrete Choice Experiment.

Zhang W, He S, Wilson L, Foix-Colonier A, Pacou M, Zhu Y Patient Prefer Adherence. 2023; 17:1421-1430.

PMID: 37334189 PMC: 10276608. DOI: 10.2147/PPA.S403252.

References

Marcus S, Zummo J, Pettit A, Stoddard J, Doshi J . Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015; 21(9):754-68. PMC: 10398026. DOI: 10.18553/jmcp.2015.21.9.754. View

Swartz M, Swanson J, Wagner H, Burns B, Hiday V . Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis. 2001; 189(9):583-92. DOI: 10.1097/00005053-200109000-00003. View

Tiihonen J, Haukka J, Taylor M, Haddad P, Patel M, Korhonen P . A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6):603-9. DOI: 10.1176/appi.ajp.2011.10081224. View

Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy M . [Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec]. Can J Psychiatry. 2011; 56(6):367-76. DOI: 10.1177/070674371105600608. View

Buckley P, Schooler N, Goff D, Hsiao J, Kopelowicz A, Lauriello J . Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2014; 41(2):449-59. PMC: 4332934. DOI: 10.1093/schbul/sbu067. View

Velligan D, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R . Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010; 16(5):306-24. DOI: 10.1097/01.pra.0000388626.98662.a0. View

Hanssens L, De Hert M, Wampers M, Reginster J, Peuskens J . Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health. 2006; 2:11. PMC: 1481604. DOI: 10.1186/1745-0179-2-11. View

Liu C, Tsai P, Chen C . Discrepancy in Taiwanese psychiatrists' preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey. Neuropsychiatr Dis Treat. 2018; 14:429-433. PMC: 5798540. DOI: 10.2147/NDT.S154490. View

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

10.

Muirhead D, Harvey C, Ingram G . Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes. Aust N Z J Psychiatry. 2006; 40(6-7):596-605. DOI: 10.1080/j.1440-1614.2006.01844.x. View

11.

Humberstone V, Wheeler A, Lambert T . An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry. 2004; 38(4):240-5. DOI: 10.1080/j.1440-1614.2004.01340.x. View

12.

Nielsen J, Jensen S, Friis R, Valentin J, Correll C . Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2014; 41(3):627-36. PMC: 4393684. DOI: 10.1093/schbul/sbu128. View

13.

Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R . Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol. 2003; 17(2):223-9. DOI: 10.1177/0269881103017002012. View

14.

Valenstein M, Ganoczy D, McCarthy J, Kim H, Lee T, Blow F . Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10):1542-50. DOI: 10.4088/jcp.v67n1008. View

15.

Vaughan K, McConaghy N, Wolf C, Myhr C, Black T . Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission. Aust N Z J Psychiatry. 2000; 34(5):801-8. DOI: 10.1080/j.1440-1614.2000.00813.x. View

16.

Chan H, Chang C, Chiang S, Chen J, Chen C, Sun H . A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. J Psychopharmacol. 2008; 24(1):91-8. PMC: 2951595. DOI: 10.1177/0269881108096070. View

17.

Hung Y, Chan H, Pan Y . Risk factors for readmission in schizophrenia patients following involuntary admission. PLoS One. 2017; 12(10):e0186768. PMC: 5658080. DOI: 10.1371/journal.pone.0186768. View

18.

Correll C, Citrome L, Haddad P, Lauriello J, Olfson M, Calloway S . The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry. 2016; 77(suppl 3):1-24. DOI: 10.4088/JCP.15032su1. View

19.

Yu H, Hsiao C, Chen K, Lee L, Chang W, Chi M . A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study. Schizophr Res. 2015; 169(1-3):400-405. DOI: 10.1016/j.schres.2015.09.006. View

20.

Leucht C, Heres S, Kane J, Kissling W, Davis J, Leucht S . Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011; 127(1-3):83-92. DOI: 10.1016/j.schres.2010.11.020. View